List view / Grid view
In this exclusive interview, Drug Target Review's Taylor Mixides interviews James Graham, CEO of Recce Pharmaceuticals, they explore the company's approach to combat the growing global threat of antimicrobial resistance (AMR). Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of…
The partial remission phase of type 1 diabetes, in which residual β-cells recover insulin production, offers new hope for therapeutic action.
Using the nicotinamide mononucleotide molecule led to proliferation of non-senescent macrophages and lessened immunosuppressive factors.
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
Endometriosis is a debilitating condition that affects millions of women worldwide, causing chronic pain, infertility, and a host of other distressing symptoms. Current treatments offer limited relief, but they do not address the cause of the disease. Professor Hugo Vankelecom, at the helm of the CurE-me project, is on a…
Foxp3 alters chromatin architecture of regulatory T cells, meaning Foxp3 could become a target for therapies that modulate immunosuppression.
Researchers find that polymerase epsilon exonuclease is an essential target for cancer diagnosis and treatments that rely on DNA damage.
New research identifies how trabeculae transform into ventricles, which could positively impact heart disease treatments.
Protein released by C. burnetti interacts with antioxidising enzyme GPX4 to prevent cell damage and death.
Six types of inflammation with various cell types and disease pathways identified may provide better treatment of rheumatoid arthritis.
Understanding how a molecular transport system inside neurons works could be used for therapeutic approaches to neurodegenerative disease.
Scientists find a way to slow the progression of Huntington’s disease by analysing DNA and find the basis of a potential treatment.
Cellulose nanofiber sheets enable analysis of EVs, and miRNAs within them, offering potential for cancer treatment and personalised medicine.
Cell therapies hold great potential for treating complex diseases, yet they face significant limitations and challenges. Current cell therapies have difficulty distinguishing between healthy and cancerous cells, often resulting in adverse effects. Vittoria's innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of…
Mitochondrial fragmentation mechanism that can cause ventilator-induced diaphragm dysfunction (VIDD) found, and a therapeutic to mitigate it.
